Though the development of specific inhibitors to KRAS or its downstream signaling molecules has been a difficult journey without success so far, recent studies show that the KRAS co-mutation status in NSCLC is associated with its responsiveness to the PD-1/PD-L1 immunotherapy, as well as the disease prognosis [34]. Here, KRAS is linked to non-small cell lung carcinoma.